MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
Wei Wang(Capital Medical University), Ruiwen Zhang(Center for Excellence in Molecular Cell Science), Xin Li(Zunyi Medical University), Jianwen Cheng(Fudan University), Jiang‐Jiang Qin(ZheJiang Academy of Agricultural Sciences), Xin‐Rong Yang(Sun Yat-sen University), Jia Fan(Nanjing Tech University), Sadanandan E. Velu(University of Alabama at Birmingham), Bo Hu(Fudan University), Bhavitavya Nijampatnam(University of Alabama at Birmingham)
Cited by 51
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
|Liver Cancer|2020|828
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine
|Nature|2012|705
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644